{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:59:53Z","timestamp":1778965193789,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2009,3,27]],"date-time":"2009-03-27T00:00:00Z","timestamp":1238112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>Abstract<\/jats:p>\n                  <jats:p>Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant and is indicated for the treatment of attention-deficit\/hyperactivity disorder. A single-centre, double-blind, randomised, placebo-controlled, 6-period crossover study evaluated the abuse potential of single oral doses of 50, 100 (equivalent to 40\u00a0mg d-amphetamine), and 150\u00a0mg LDX, 40\u00a0mg d-amphetamine and 200\u00a0mg diethylpropion in 36 individuals with a history of stimulant abuse. On the primary abuse liability measure, maximum change of the Drug Rating Questionnaire-Subject Liking Scale compared with placebo, d-amphetamine and diethylpropion showed significant differences of 4.5 and 4.0 units, respectively ( P\u00a0&lt;\u00a00.001 for both vs placebo). LDX, administered at 50, 100 and 150\u00a0mg, showed nonsignificant differences of 2.0 and 2.1 units, respectively, at the two lower doses but a significant ( P\u00a0&lt;\u00a00.001 vs placebo) difference of 6.1 units at the highest dose. Subjects significantly favoured d-amphetamine 40\u00a0mg versus LDX 100\u00a0mg (2.4 units difference; P\u00a0&lt;\u00a00.05). There was no significant difference in liking scores between d-amphetamine 40\u00a0mg and LDX 150\u00a0mg. Drug Rating Questionnaire-Subject Feel-Drug-Effect score was significantly lower for 100\u00a0mg LDX than for 40\u00a0mg d-amphetamine. There were no statistically significant differences between LDX and diethylpropion hydrochloride, a Schedule IV amphetamine-like stimulant, on abuse-related liking scores. Cardiovascular responses of LDX and d-amphetamine were similar at equivalent doses. In conclusion, at an equivalent amount of amphetamine base taken orally, LDX 100\u00a0mg had attenuated responses on measures of abuse liability compared with immediate-release d-amphetamine 40\u00a0mg. Abuse-related liking scores of LDX at a dose corresponding to a 50% higher amphetamine base (LDX 150\u00a0mg) were similar to d-amphetamine 40\u00a0mg.<\/jats:p>","DOI":"10.1177\/0269881109103113","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T12:16:33Z","timestamp":1238415393000},"page":"419-427","source":"Crossref","is-referenced-by-count":130,"title":["Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse"],"prefix":"10.1177","volume":"23","author":[{"given":"DR","family":"Jasinski","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins University, Baltimore, MD, USA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Formerly of New River Pharmaceuticals, Inc., Belvedere, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,3,27]]},"reference":[{"key":"atypb1","first-page":"894","volume":"47","author":"American Academy of Child and Adolescent Psychiatry","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.4.1033"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.015"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66915-2"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(07)80083-X"},{"key":"atypb6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"Folstein MF","year":"1975","journal-title":"J Psychiatr Res"},{"key":"atypb7","unstructured":"Jasinski D\u2004 Krishnan S\u2004 (2006) Pharmacokinetics of oral lisdexamfetamine dimesylate (LDX; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse. Poster presented at: US Psychiatric and Mental Health 19th Annual Congress; November 15\u201319, 2006; New Orleans, LA."},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1177\/026988110001400107"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200005000-00004"},{"key":"atypb10","unstructured":"Jasinski DR\u2004 Krishnan S\u2004 (2006) Abuse liability of intravenous L-lysine-d-amphetamine (NRP104). Presented at: College on Problems of Drug Dependence 68th Annual Scientific Meeting; June 17\u201322, 2006; Scottsdale, AZ. Abstract 365."},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974164645"},{"key":"atypb12","unstructured":"Krishnan S\u2004 Jasinski D\u2004 (2006) Pharmacokinetics of oral NRP104\/SPD489 (lisdexamfetamine dimesylate) versus d-amphetamine in healthy adults with a history of stimulant abuse. Abstract presented at: The College on Problems of Drug Dependence 68th Annual Meeting; June 17\u201322, 2006; Scottsdale, AZ."},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971122part1245"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000215326.51175.eb"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.01.006"},{"key":"atypb16","unstructured":"Shojaei A\u2004 Ermer JC\u2004 Krishnan S\u2004 (2007) Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at: the 160th Annual Meeting of the American Psychiatric Association; May 19\u201324, 2007; San Diego, CA. Poster NR 740."},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.11.1909"},{"key":"atypb18","unstructured":"Wigal SB\u2004 Kollins SH\u2004 Squires LA\u2004 Childress AC\u2004 Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13\u00a0hours in an analog classroom study in children with attention-deficit\/hyperactivity disorder. Poster presented at: The American Academy of Child & Adolescent Psychiatry's 55th Annual Meeting; October 28-November 2, 2008; Chicago, IL."}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881109103113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881109103113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:21Z","timestamp":1777507881000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881109103113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,27]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1177\/0269881109103113"],"URL":"https:\/\/doi.org\/10.1177\/0269881109103113","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,27]]}}}